Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response of carmoterol in COPD
NCT00782535Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Dec 2008
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of carmoterol in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Forced Expiratory Volume in 1 Second. Started Dec 2008; status: completed.
02
Drugs
carmoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00782535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00782535.